NCT04711252
Last Updated Date: September 11, 2026
On September 11, 2026, AstraZeneca reported that this frontline trial, testing camizestrant plus palbociclib against anastrozole plus palbociclib in previously untreated ER-positive, HER2-negative advanced breast cancer, did not reach statistical significance on its main progression-free survival goal, despite a numerical improvement favoring the camizestrant arm. The company said the combination’s safety profile matched what’s already known about each drug individually, with no new safety concerns identified.
